Search Result

Results for "

bone+disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminotransferases (Transaminases) (1) AMPK (1) Amylin Receptor (2) AP-1 (1) Apoptosis (5) Autophagy (2) Bacterial (1) c-Fms (1) Cathepsin (1) CGRP Receptor (2) Drug Derivative (2) HDAC (1) Integrin (1) MMP (1) NF-κB (1) Notch (1) Nuclear Factor of activated T Cells (NFAT) (1) p62 (2) PAI-1 (1) Phosphatase (1) PTHR (2) RANKL/RANK (2) Reactive Oxygen Species (ROS) (1) Salt-inducible Kinase (SIK) (1) SARS-CoV (1) VD/VDR (1) Virus Protease (1) γ-secretase (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (3) Endocrinology (2) Infection (2) Inflammation/Immunology (6) Metabolic Disease (13) Neurological Disease (3)

By Targets:

Aminotransferases (Transaminases) (1)

AMPK (1)

Amylin Receptor (2)

AP-1 (1)

Apoptosis (5)

Autophagy (2)

Bacterial (1)

c-Fms (1)

Cathepsin (1)

CGRP Receptor (2)

Drug Derivative (2)

HDAC (1)

Integrin (1)

MMP (1)

NF-κB (1)

Notch (1)

Nuclear Factor of activated T Cells (NFAT) (1)

p62 (2)

PAI-1 (1)

Phosphatase (1)

PTHR (2)

RANKL/RANK (2)

Reactive Oxygen Species (ROS) (1)

Salt-inducible Kinase (SIK) (1)

SARS-CoV (1)

VD/VDR (1)

Virus Protease (1)

γ-secretase (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (3)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (6)

Metabolic Disease (13)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112904

XRK3F2 Maximum Cited Publications 7 Publications Verification	p62 Autophagy	Cancer
XRK3F2 is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma .

HY-B0657A

Clodronic acid disodium salt 4 Publications Verification Clodronate disodium salt	Apoptosis	Metabolic Disease Cancer
Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis .

HY-W193545A

ERG240 5 Publications Verification	Aminotransferases (Transaminases)	Inflammation/Immunology Cancer
ERG240 is an oral active branched-chain amino acid aminotransferase 1 (BCAT1) inhibitor. ERG240 can be used for the research of cancer, rheumatoid arthritis, and bone disease .

HY-B0657

Clodronic acid 4 Publications Verification Clodronate	Apoptosis	Metabolic Disease Cancer
Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis .

HY-P990552A

huATN-658	PAI-1 Integrin	Cancer
huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .

HY-N15723

Dipsacus saponin A	Others	Others
Dipsacus saponin A is an orally active triterpenoid saponin found in the roots of Dipsacus asper. Dipsacus saponin A promotes bone repair by regulating osteoblast activity and inhibiting osteoclast function. Dipsacus saponin A is promising for research of bone diseases such as fracture healing and osteoporosis .

HY-107093

MBC-11	Apoptosis	Cancer
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research .

HY-116640

Amorphigenin	AP-1 Nuclear Factor of activated T Cells (NFAT) AMPK Autophagy	Metabolic Disease Inflammation/Immunology Endocrinology
Amorphigenin is a trothotenone compound. Amorphigenin inhibits osteoclast differentiation by suppressing the expression of c-Fos and NFATc1 in activated T cells. Amorphigenin degrades melanosome proteins by activating the AMPK-dependent autophagy pathway, but not in dependence of the mTOR pathway. Amorphigenin significantly protects bone mass and reduces bone erosion in a mouse model of inflammatory bone loss. Amorphigenin can be used to study inflammatory bone diseases, postmenopausal osteoporosis, and skin pigmentation disorders .

HY-U00358

Compound 2	Drug Derivative	Metabolic Disease Cancer
Compound 2 is an active compound used for the research of metabolic bone diseases.

HY-N8837

Trifloroside	MMP	Metabolic Disease
Trifloroside is a secoiridoid glycoside with antioxidant effects. Trifloroside induces osteogenic effects through osteoblast differentiation, adhesion, migration, and mineral apposition. Trifloroside has the potential for osteoblast-mediated bone diseases research .

HY-176946

PTH1R agonist 4	PTHR	Metabolic Disease
PTH1R agonist 4 (Example 63) is a parathyroid hormone 1 receptor (PTH1R) agonist with a pEC₅₀ value greater than 7. PTH1R agonist 4 can be used for the study of bone diseases, such as osteoporosis .

HY-108303

Neridronate sodium	Phosphatase	Inflammation/Immunology
Neridronate sodium is a bone resorption factors inhibitor. Neridronate sodium can be used in research on diseases such as metabolic bone disease and musculoskeletal pain .

HY-100701

Dutacatib	Cathepsin SARS-CoV Virus Protease	Infection Cancer
Dutacatib is inhibitor for SARS-CoV-2 3CL ^pro and cathepsin K, which exhibits antiviral activity and ameliorates the cancer-induced bone diseases .

HY-176945

PTH1R agonist 3	PTHR	Metabolic Disease
PTH1R agonist 3 (Example 47) is a parathyroid hormone 1 receptor (PTH1R) agonist with a pEC₅₀ value of less than 6. PTH1R agonist 3 can be used for the study of bone diseases, such as osteoporosis .

HY-101149

YKL-05-093	Salt-inducible Kinase (SIK) HDAC RANKL/RANK	Inflammation/Immunology
YKL-05-093 is a salt-induced kinase (SIK) inhibitor (SIK2: K_d = 7.1 nM). YKL-05-093 reduces the phosphorylation level of HDAC4/5/CRTC2, inhibits SOST expression, and stimulates RANKL expression in vitro and in vivo. YKL-05-093 can be used in research on bone diseases .

HY-76937

Impurity of Doxercalciferol	VD/VDR	Endocrinology
Impurity of Doxercalciferol is an impurity of doxercalciferol, which is a synthetic analog of ergocalciferol (vitamin D2), used as a agent for secondary hyperparathyroidism and metabolic bone disease, and it suppresses parathyroid synthesis and secretion.

HY-N13301

Aloe vera	Bacterial Reactive Oxygen Species (ROS)	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Aloe vera is an herbal plant known for its anti-inflammatory, antibacterial, anticancer, antioxidant, heart-protective, and wound-healing properties. Aloe vera can be used in research for tumors, diabetes, bone diseases, and cardiovascular diseases .

HY-107093B

MBC-11 triethylamine	Apoptosis	Cancer
MBC-11 triethylamine is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential for tumor-induced bone disease (TIBD) research .

HY-107093A

MBC-11 trisodium	Apoptosis	Cancer
MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. MBC-11 trisodium has the potential for tumor-induced bone disease (TIBD) research .

HY-N13219

Angelica Extract	Others	Metabolic Disease
Angelica Extract is an angelica extract, and its components include: Ligustilide. Angelica Extract can effectively inhibit the differentiation of osteoclasts, regulate osteoclastogenesis and/or bone loss. Angelica Extract has the potential to be used in the study of various bone diseases caused by excessive bone resorption. .

HY-N15719

Dipsacus saponin R	Others	Others
Dipsacus saponin R (Compound 1) is an orally active triterpenoid saponin found in Radix Dipsaci. Dipsacus saponin R promotes bone formation and repair by regulating osteoblast activity or inhibiting osteoclast function. Dipsacus saponin R is promising for research of bone diseases such as osteoporosis and fracture healing .

HY-161084

CSF1R-IN-18	c-Fms	Neurological Disease Cancer
CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases .

HY-145428

BT-GSI	Notch γ-secretase	Cancer
BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression .

HY-W746269

KCA 098	Drug Derivative	Metabolic Disease
KCA 098 is an orally active benzofuroquinoline derivative. KCA 098 can inhibit bone resorption and stimulat bone formation of chick embryo. KCA 098 can increase calcium and phosphorus content as well as the amount of force required to break the femur from ovariectomized rats. KCA 098 can be used for the research of bone diseases .

HY-W438351

1,3-Dibenzyl-5-fluorouracil	RANKL/RANK	Metabolic Disease
1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor of osteoclastogenesis. 1,3-Dibenzyl-5-fluorouracil inhibits the expression of osteoclast markers by downregulating the receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) signaling pathways. 1,3-Dibenzyl-5-fluorouracil can be used in the study of metabolic bone diseases .

HY-P992312

APX008	NF-κB	Inflammation/Immunology
APX008 is a monoclonal antibody that targets RANKL and is a RANKL inhibitor. APX008 can be used in research on bone diseases.

HY-185234

CTR/AMYR activator-1	CGRP Receptor Amylin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
CTR/AMYR activator-1 (S configuration of compound 122) is a CTR/AMYR activator. CTR/AMYR activator-1 can be used in the research of bone diseases, metabolic diseases, cardiovascular diseases, and neurodegenerative diseases .

HY-185234A

(R)-CTR/AMYR activator-1	Amylin Receptor CGRP Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
(R)-CTR/AMYR activator-1 (Compound 122) is a CTR/AMYR activator with EC₅₀ values of 0.8 and 0.73 nM. (R)-CTR/AMYR activator-1 can used for the researches of bone diseases, metabolic diseases, cardiovascular diseases, and neurodegenerative diseases .

HY-112904A

XRK3F2 free base	p62	Cancer
XRK3F2 free base is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 free base blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 free base can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma .

Cat. No.	Product Name

HY-L131

Osteogenesis Compound Library	886 compounds
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health. Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc. MCE offers a unique collection of 886 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

Osteogenesis Compound Library

886 compounds

Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.

Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.

MCE offers a unique collection of 886 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

HY-L018

TGF-beta/Smad Compound Library	413 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc. MCE designs a unique collection of 413 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

TGF-beta/Smad Compound Library

413 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 413 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

Cat. No.	Product Name	Target	Research Area	Image

HY-P990552A

huATN-658	PAI-1 Integrin	Cancer
huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .

HY-P992312

APX008	NF-κB	Inflammation/Immunology
APX008 is a monoclonal antibody that targets RANKL and is a RANKL inhibitor. APX008 can be used in research on bone diseases.

Dipsacus saponin A	Triterpenes Terpenoids Dipsacaceae Dipsacus asper Wall. Plants Source Classification	Others
Dipsacus saponin A is an orally active triterpenoid saponin found in the roots of Dipsacus asper. Dipsacus saponin A promotes bone repair by regulating osteoblast activity and inhibiting osteoclast function. Dipsacus saponin A is promising for research of bone diseases such as fracture healing and osteoporosis .

Amorphigenin	Structural Classification Flavonoids Leguminosae Amorpha fruticosaL. Plants Other Flavonoids Source Classification	AP-1 Nuclear Factor of activated T Cells (NFAT) AMPK Autophagy
Amorphigenin is a trothotenone compound. Amorphigenin inhibits osteoclast differentiation by suppressing the expression of c-Fos and NFATc1 in activated T cells. Amorphigenin degrades melanosome proteins by activating the AMPK-dependent autophagy pathway, but not in dependence of the mTOR pathway. Amorphigenin significantly protects bone mass and reduces bone erosion in a mouse model of inflammatory bone loss. Amorphigenin can be used to study inflammatory bone diseases, postmenopausal osteoporosis, and skin pigmentation disorders .

Trifloroside	Structural Classification Gentiana scabra Bunge Iridoids Terpenoids Gentianaceae Plants Source Classification	MMP
Trifloroside is a secoiridoid glycoside with antioxidant effects. Trifloroside induces osteogenic effects through osteoblast differentiation, adhesion, migration, and mineral apposition. Trifloroside has the potential for osteoblast-mediated bone diseases research .

Aloe vera	Structural Classification Natural Products Liliaceae Aloe vera (L.) Burm. f. Plants Source Classification	Bacterial Reactive Oxygen Species (ROS)
Aloe vera is an herbal plant known for its anti-inflammatory, antibacterial, anticancer, antioxidant, heart-protective, and wound-healing properties. Aloe vera can be used in research for tumors, diabetes, bone diseases, and cardiovascular diseases .

Dipsacus saponin R	Triterpenes Structural Classification Terpenoids Dipsacaceae Dipsacus asper Wall. Plants Pentacyclic Triterpenoids Source Classification	Others
Dipsacus saponin R (Compound 1) is an orally active triterpenoid saponin found in Radix Dipsaci. Dipsacus saponin R promotes bone formation and repair by regulating osteoblast activity or inhibiting osteoclast function. Dipsacus saponin R is promising for research of bone diseases such as osteoporosis and fracture healing .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks